Atheroprotective effect of Oleoylethanolamide (OEA) targeting oxidized LDL

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Fan, Angran ^a   Wu, Xiaofeng ^a   Wu, Huijuan ^a   Li, Long ^a   Huang, Rui ^a   Zhu, Yueyong ^b   Qiu, Yan ^a   Fu, Jin ^a   Ren, Jie ^a   Zhu, Chenggang ^c  

^a XIAMEN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; N OLEOYLETHANOLAMINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RNA; TUMOR NECROSIS FACTOR ALPHA; LOW DENSITY LIPOPROTEIN; OLEIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALORIC INTAKE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; NONHUMAN; OXIDATION; PATHOGENESIS; PROTEIN MODIFICATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; COX 2 GENE; ENDOTHELIUM CELL; GENE; IL 6 GENE; INOS GENE; LIPID OXIDATION; M CFS GENE; MOUSE; PPAR ALPHA GENE; PROPHYLAXIS; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; CELL LINE; CELL MOTION; DRUG EFFECTS; METABOLISM;

ANIMALIA; MUS; RATTUS;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; LIPOPROTEINS, LDL; MICE; OLEIC ACIDS; PPAR ALPHA; RATS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84921417873     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085337     Document Type: Article

References (48)

1. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med. 340: 115-126.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924. (Pubitemid 19101597)
3. Fantuzzi G, Mazzone T (2007) Adipose tissue and atherosclerosis: Exploring the connection. Arterioscler Thromb Vasc Biol. 27: 996-1003. (Pubitemid 46641984)
4. Glass CK, Witztum JL (2001) Atherosclerosis. The road ahead. Cell. 104: 503-516.
5. Berger J, Moller DE (2002) The mechanisms of action of ppars. Annu Rev Med. 53: 409-435. (Pubitemid 34177889)
6. Bocher V, Chinetti G, Fruchart JC, Staels B (2002) Role of the peroxisome proliferator-activated receptors (ppars) in the regulation of lipids and inflammation control. J Soc Biol. 196: 47-52.
7. Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, et al. (2010) A selective peroxisome proliferator-activated receptor alpha agonist, cp-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther 333: 844-853.
8. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of ppars in atherosclerosis. Trends Mol Med. 8: 422-430. (Pubitemid 34975988)
9. Evans RM, Barish GD, Wang YX (2004) Ppars and the complex journey to obesity. Nature Medicine 10: 355-361. (Pubitemid 38508511)
10. Kooistra T, Verschuren L, de Vries-van der Weij J, Koenig W, Toet K, et al. (2006) Fenofibrate reduces atherogenesis in apoe*3leiden mice: Evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol. 26: 2322-2330.
11. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, et al. (2000) Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 275: 16638-16642. (Pubitemid 30398891)
12. Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 61: 393-416. (Pubitemid 38316578)
13. Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470. (Pubitemid 41134276)
14. Keating GM, Croom KF (2007) Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 67: 121-153. (Pubitemid 46105094)
15. LoVerme JL, Fu J, Astarita G, La Rana G, Russo R, et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-{alpha} mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 67: 15-19. (Pubitemid 40069962)
16. Suardiaz M, Estivill-Torrus G, Goicoechea C, Bilbao A, Rodriguez de Fonseca F (2007) Analgesic properties of oleoylethanolamide (oea) in visceral and inflammatory pain. Pain 133: 99-110.
17. Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 95: 829-836.
18. Neve BP, Fruchart JC, Staels B (2000) Role of the peroxisome proliferator-activated receptors (ppar) in atherosclerosis. Biochemical Pharmacology. 60: 1245-1250.
19. Zahradka P, Yurkova N, Litchie B, Moon MC, Del Rizzo DF, et al. (2003) Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation. Mol Cell Biochem. 246: 105-110. (Pubitemid 36798729)
20. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res. 94: 1168-1178. (Pubitemid 38656403)
21. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, et al. (2005) Ppar alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16ink4a. J Clin Invest. 115: 3228-3238. (Pubitemid 41567587)
22. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, et al. (2001) Ppar-alpha and ppar-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the abca1 pathway. Nature Medicine. 7: 53-58. (Pubitemid 32095642)
23. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor ppar-alpha. Nature. 425: 90-93. (Pubitemid 37101723)
24. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, et al. (2007) Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem. 282: 1518-1528. (Pubitemid 47076553)
25. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, et al. (2008) The lipid messenger oea links dietary fat intake to satiety. Cell Metabolism. 8: 281-288.
26. Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, et al. (2004) Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (ppar-alpha). J Biol Chem. 279: 27849-27854. (Pubitemid 38900052)
27. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D (2005) Oleoylethanolamide, an endogenous ppar-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 48: 1147-1153. (Pubitemid 40725987)
28. Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, et al. (2008) Biological functions and metabolism of oleoylethanolamide. Lipids. 43: 887-894.
29. Yang Y, Chen M, Georgeson KE, Harmon CM (2007) Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. Am J Physiol Regul Integr Comp Physiol. 292: R235-241. (Pubitemid 46089835)
30. Astarita G, Di Giacomo B, Gaetani S, Oveisi F, Compton TR, et al. (2006) Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther. 318: 563-570. (Pubitemid 44061230)
31. Zahradka P, Wright B, Fuerst M, Yurkova N, Molnar K, et al. (2006) Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J Pharmacol Exp Ther. 317: 651-659.
32. Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, et al. (2008) The pparalpha/p16ink4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circulation Research. 103: 1155-1163.
33. Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 83: 456S-460S.
34. Libby P (2002) Inflammation in atherosclerosis. Nature. 420: 868-874.
35. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, et al. (2004) Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by pparalpha, beta/delta, and gamma. J Clin Invest. 114: 1564-1576. (Pubitemid 40385547)
36. Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, et al. (2007) Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 116: 1404-1412. (Pubitemid 47417567)
37. Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 454: 470-477.
38. Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res. 95: 858-866. (Pubitemid 39435000)
39. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, et al. (2002) Ppar activators as antiinflammatory mediators in human t lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 90: 703-710. (Pubitemid 34640890)
40. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, et al. (1998) Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia iib. Int J Clin Pharmacol Ther. 36: 345-349. (Pubitemid 28271555)
41. Berger JP, Akiyama TE, Meinke PT (2005) Ppars: Therapeutic targets for metabolic disease. Trends Pharmacol Sci. 26: 244-251. (Pubitemid 40603072)
42. Chinetti-Gbaguidi G, Fruchart JC, Staels B (2005) Role of the ppar family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: New approaches to therapy. Curr Opin Pharmacol. 5: 177-183. (Pubitemid 40378750)
43. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-coa synthetase genes by ppar a and pparc activators. J Biol Chem. 272: 28210-28217. (Pubitemid 27517759)
44. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, et al. (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093. (Pubitemid 28512236)
45. Keech A, Simes RJ, Barter P, Best J, Scott R, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the field study): Randomised controlled trial. Lancet. 366: 1849-1861.
46. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. (1987) Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317: 1237-1245. (Pubitemid 17147964)
47. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, et al. (1988) Lipid alterations and decline in the incidence of coronary heart disease in the helsinki heart study. JAMA 260: 641-651.
48. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 341: 410-418. (Pubitemid 29362514)